U
Ursula Schmidt-Erfurth
Researcher at Medical University of Vienna
Publications - 703
Citations - 34745
Ursula Schmidt-Erfurth is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Macular degeneration & Optical coherence tomography. The author has an hindex of 82, co-authored 638 publications receiving 28143 citations. Previous affiliations of Ursula Schmidt-Erfurth include University of Vienna & Yahoo!.
Papers
More filters
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Book ChapterDOI
Unsupervised Anomaly Detection with Generative Adversarial Networks to Guide Marker Discovery
TL;DR: AnoGAN, a deep convolutional generative adversarial network is proposed to learn a manifold of normal anatomical variability, accompanying a novel anomaly scoring scheme based on the mapping from image space to a latent space.
Journal ArticleDOI
The RESTORE Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
Paul Mitchell,Francesco Bandello,Ursula Schmidt-Erfurth,Gabriele E. Lang,Pascale Massin,Reinier O. Schlingemann,Florian K. P. Sutter,Christian Simader,Gabriela Burian,Ortrud Gerstner,Andreas Weichselberger +10 more
TL;DR: Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over standard laser in patients with visual impairment due to DME and had a safety profile in DME similar to that in age-related macular degeneration.
Journal ArticleDOI
f-AnoGAN: Fast unsupervised anomaly detection with generative adversarial networks.
TL;DR: Fast AnoGAN (f‐AnoGAN), a generative adversarial network (GAN) based unsupervised learning approach capable of identifying anomalous images and image segments, that can serve as imaging biomarker candidates is presented.
Journal ArticleDOI
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies
Ursula Schmidt-Erfurth,Peter K. Kaiser,Jean-François Korobelnik,David M. Brown,Victor Chong,Quan Dong Nguyen,Allen C. Ho,Yuichiro Ogura,Christian Simader,Glenn J. Jaffe,Jason S. Slakter,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Olaf Sowade,Oliver Zeitz,Oliver Zeitz,Christiane Norenberg,Rupert Sandbrink,Rupert Sandbrink,Jeffrey S. Heier +23 more
TL;DR: All aflibercept and ranibizumab groups were equally effective in improving BCVA and preventing BCVA loss at 96 weeks, and the 2q8 a flibercept group was similar to ranibIZumab in visual acuity outcomes during 96 weeks, but with an average of 5 fewer injections.